A subset of products subject to the biologics transition process in March 2020 may continue using drug master file information after they become biologics license applications, even though the US Food and Drug Administration currently prevents the practice.
The FDA issued a proposed rule 27 June that would allow these products, which include some reproductive hormones and enzymes,...
Welcome to Pink Sheet
Create an account to read this article
Already a subscriber?